New pill aims to fight Obesity-Linked inflammation
Disease control
Recruiting now
This study tests an experimental drug called BGE-102 in 160 adults with obesity and heart risk factors. The goal is to see if it lowers inflammation (measured by hsCRP) safely. Participants take either BGE-102 or a placebo daily for 12 weeks.
Phase: PHASE2 • Sponsor: BioAge Labs, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC